Publications by authors named "Lilian Arruda"
Clinical research is the cornerstone of improvements in cancer care. However, it has been conducted predominantly in high-income countries with few clinical trials available in Brazil and other low-and-middle-income countries (LMIC). Of note, less than one-third of registered clinical trials addressing some of the most commonly diagnosed cancers (breast, lung and cervical) recruited patients from LMIC in the last years.
View Article and Find Full Text PDFArticle Synopsis
- Epidemiological cancer research is crucial for understanding tumors and developing new treatments, yet Brazil has low participation in clinical trials, with only 2.2% of ongoing trials available despite 625,000 new cancer cases in 2022.
- An online survey of 109 Brazilian physicians, mainly oncologists, aimed to assess their involvement in research and identify barriers to conducting clinical trials.
- Results showed that while 89.9% of physicians found clinical trial participation important, 31.2% invite less than 1% of their patients to join trials, mainly due to a shortage of available studies and qualified personnel.
Hormone receptor-negative as a predictive factor for pathologic complete response to neoadjuvant therapy in breast cancer.
Einstein (Sao Paulo)
January 2019
Objective: To define a predictive factor for pathologic complete response, compare the oncologic outcomes associated with the degree of pathologic response after neoadjuvant chemotherapy, and to analyze pathologic complete response as a prognostic factor for overall survival and progression-free survival.
Methods: A retrospective study of patients admitted to Hospital Estadual Mário Covas and Hospital Anchieta from 2008 to 2012, with locally advanced breast cancer. Hormone receptor status, HER2 status, histologic and nuclear grade, age upon diagnosis and histological type of the tumor were analyzed.